Market Place
Sourcing Support
Candel Therapeutics Issues Inducement Grants Under Nasdaq Rules
02 Apr 2026 //
GLOBENEWSWIRE
Candel Therapeutics Awards Inducement Grants Under Nasdaq Rules
02 Mar 2026 //
GLOBENEWSWIRE
Candel Secures $100M RTW Royalty Deal for CAN-2409
19 Feb 2026 //
GLOBENEWSWIRE
Candel Therapeutics Highlights Immunotherapy Advances At SITC
04 Nov 2025 //
GLOBENEWSWIRE
Candel Therapeutics To Present at Jefferies Global Health Conf
03 Nov 2025 //
GLOBENEWSWIRE
Candel Therapeutics Secures $130M Term Loan With Trinity Capital
14 Oct 2025 //
GLOBENEWSWIRE
Candel Therapeutic Unveils Can-2409 Ph 3 Trial In Prostate Cancer
29 Sep 2025 //
GLOBENEWSWIRE
Candel Therapeutics Appoints Immunotherapy Pioneer Carl H. June
02 Sep 2025 //
GLOBENEWSWIRE
Candel Therapeutics to Present at Investor Conferences
28 Aug 2025 //
GLOBENEWSWIRE
Candel Therapeutics Reports Q2 2025 Financials and Corporate
14 Aug 2025 //
GLOBENEWSWIRE
Candel to Speak at Canaccord Genuity 45th Growth Conference
30 Jul 2025 //
GLOBENEWSWIRE
Candel Therapeutics Announces $15M Stock Offering
24 Jun 2025 //
GLOBENEWSWIRE
Candel Therapeutics Names Charles Schoch CFO
23 Jun 2025 //
GLOBENEWSWIRE
Candel Therapeutics Appoints Maha Radhakrishnan to Board
06 Jun 2025 //
GLOBENEWSWIRE
Candel To Host Call on CAN-2409 Ph3 Data After ASCO
27 May 2025 //
GLOBENEWSWIRE
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results
22 May 2025 //
GLOBENEWSWIRE
Biopsies Illuminate Potential of Candel`s Prostate Cancer Drug
22 May 2025 //
FIERCE BIOTECH
Candel Therapeutics to Present at Upcoming Investor Conferences
06 May 2025 //
GLOBENEWSWIRE
Candel Therapeutics Announces Positive Phase 3 Results at ASCO 2025
23 Apr 2025 //
GLOBENEWSWIRE
Candel Therapeutics and IDEA Pharma Partner to Advance CAN-2409
20 Mar 2025 //
GLOBENEWSWIRE
Candel Therapeutics Appoints Pancreatic Cancer Expert Elizabeth
18 Mar 2025 //
GLOBENEWSWIRE
Candel Therapeutics Reports Q4 and Full Year 2024 Results
13 Mar 2025 //
GLOBENEWSWIRE
Candel Updates Pipeline Progress And 2025 Value Drivers
13 Jan 2025 //
GLOBENEWSWIRE
Candel Therapeutics Closes Public Offering, Underwriter Option
16 Dec 2024 //
GLOBENEWSWIRE
Candel Therapeutics Announces $80 Million Proposed Public Offering
12 Dec 2024 //
GLOBENEWSWIRE
Candel Therapeutics Announces Pricing of Public Offering
12 Dec 2024 //
GLOBENEWSWIRE
Candel Achieves Primary Endpoint in Prostate Cancer Trial
11 Dec 2024 //
GLOBENEWSWIRE
Candel Therapeutics Reports Q3 2024 Results & Highlights
14 Nov 2024 //
GLOBENEWSWIRE
C&el Therapeutics to Present at Jefferies London Healthcare Conf
07 Nov 2024 //
GLOBENEWSWIRE
Candel Showcases Cancer Therapy Candidates at IOVC 2024
28 Oct 2024 //
#N/A
Candel To Present CAN-3110 Data In Melanoma At SITC 2024
04 Oct 2024 //
GLOBENEWSWIRE
Candel Therapeutics to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
Candel Therapeutics Reports Q2 2024 Results And Corporate Highlights
13 Aug 2024 //
GLOBENEWSWIRE
Candel To Participate In H.C. Wainwright Immune Cell Engager Conference
18 Jun 2024 //
GLOBENEWSWIRE
Candel Therapeutics to Join Russell 3000® Index
11 Jun 2024 //
GLOBENEWSWIRE
Candel`s CAN-2409 Positive Phase 2 Data In Borderline Resectable Pancreatic
03 Jun 2024 //
ACCESSWIRE
Candel Can-2409 Os Results: Phase 2 Nsclc Ici Nonresponsive Asco24
23 May 2024 //
GLOBENEWSWIRE
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
22 May 2024 //
GLOBENEWSWIRE
Candel To Host NSCLC R&D Panel At ASCO 2024
20 May 2024 //
GLOBENEWSWIRE
Candel Therapeutics Reports Q1 2024 Results, Corporate Highlights
14 May 2024 //
GLOBENEWSWIRE
Candel to Present at ASCO 2024 Annual Meeting
25 Apr 2024 //
GLOBENEWSWIRE
Candel Presents AACR Data on Solid Tumor Immunotherapy
09 Apr 2024 //
GLOBENEWSWIRE
Candel Announces Positive Data from Ph 2 Trial of CAN-2409 in Pancreatic Cancer
04 Apr 2024 //
GLOBENEWSWIRE
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Candel Therapeutics Announces an Upcoming Presentation at the AACR
05 Mar 2024 //
GLOBENEWSWIRE
Candel Therapeutics Sets Path to Success
05 Feb 2024 //
GLOBENEWSWIRE
Candel Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
12 Dec 2023 //
GLOBENEWSWIRE
Candel Announces Restructuring to Prioritize Resources on Key Value Drivers
28 Nov 2023 //
GLOBENEWSWIRE
Candel’s flame dims as layoffs hit 50% of the team
28 Nov 2023 //
FIERCE BIOTECH
Candel Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Candel Therapeutics Presents Preclinical Data from enLIGHTEN Discovery Platform
04 Nov 2023 //
GLOBENEWSWIRE
Candel Therapeutics Announces Positive Interim Data from Phase 2 of CAN-2409
03 Nov 2023 //
GLOBENEWSWIRE
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations
27 Sep 2023 //
GLOBENEWSWIRE
Candel Reports Initial Survival Data from Phase 2 Clinical Trial of CAN-2409
26 Sep 2023 //
GLOBENEWSWIRE
Candel to Participate in the H.C. Wainwright 25th Annual Global Conference
06 Sep 2023 //
GLOBENEWSWIRE
Candel Therapeutics Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Candel to Participate in the Canaccord Genuity 43rd Annual Growth Conference
02 Aug 2023 //
GLOBENEWSWIRE
Candel Announces It Expects to Report Data from Phase 2 Trial of CAN-2409
13 Jun 2023 //
GLOBENEWSWIRE
Candel Appoints Nicoletta Loggia, PhD, RPh to its Board of Directors
08 Jun 2023 //
GLOBENEWSWIRE
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
05 Jun 2023 //
GLOBENEWSWIRE
